Why did Gilead Sciences adopt a new deferred compensation plan and amend its existing ones?

Gilead adopted the new 2005 Deferred Compensation Plan and amended its Severance Plan primarily to comply with Section 409A of the Internal Revenue Code. This section introduced new, stricter regulations regarding the timing and nature of nonqualified deferred compensation arrangements and severance pay, impacting how these benefits are taxed and administered.

What are the key changes for employees participating in the new deferred compensation or severance plans?

For the deferred compensation plan, participants will experience a mandatory six-month delay for payments upon separation from service (for specified employees), stricter limitations on unscheduled withdrawals, and new requirements for changing deferral or distribution elections. For the severance plan, certain officers will face a six-month delay in receiving severance payments after termination, although benefits like outplacement services and medical continuation are not delayed. Additionally, severance payments will now be made in installments aligned with the company's payroll cycle, removing the previous option for lump-sum payments for many participants.

What is the significance of the increase in authorized shares of common stock?

The doubling of authorized common stock from 700,000,000 to 1,400,000,000 shares provides Gilead with significantly more flexibility for future capital-raising activities, stock-based compensation, acquisitions, or other corporate transactions. This is a substantial increase, indicating potential for future growth and strategic initiatives.

How does the amendment to the 2004 Equity Incentive Plan affect share awards?

The amendment increases the total number of shares available for the plan and specifically boosts the number of shares that can be granted as 'full value' awards (like restricted stock and performance shares). It also introduces new limits on performance unit grants, capping them at 200,000 shares per employee annually, ensuring better control over equity dilution while still allowing for competitive compensation packages.

GILD 8-K: Material Agreements & Corporate Changes

Summary

This 8-K filing from Gilead Sciences, Inc. (GILD) primarily details several material amendments and adoptions of corporate plans and governance structures, largely aimed at complying with new IRS regulations under Section 409A of the Internal Revenue Code. Key changes include the adoption of a new 2005 Deferred Compensation Plan, which replaces a prior plan and introduces stricter rules regarding distributions and withdrawals to align with Section 409A. The company also amended its Severance Plan to incorporate similar 409A compliance measures, notably a mandatory six-month delay for certain executive severance payments after termination. Additionally, the filing reports significant increases in authorized shares of common stock and preferred stock, alongside amendments to the 2004 Equity Incentive Plan to increase share availability and impose limits on awards, and the approval of the Code Section 162(m) Bonus Plan.

Key Highlights

1Gilead adopted the 2005 Deferred Compensation Plan and froze its Prior Plan to comply with Section 409A of the Internal Revenue Code, altering distribution and withdrawal rules for key employees and directors.
2The Severance Plan was amended to comply with Section 409A, mandating a six-month delay for severance payments to certain officers after termination of employment, though some benefits like outplacement services remain unaffected.
3The number of authorized shares of common stock was doubled from 700,000,000 to 1,400,000,000, pending stockholder approval which was obtained.
4The 2004 Equity Incentive Plan was amended to increase the authorized shares for issuance by 10,000,000 and the number of shares available for 'full value' awards from 2,900,000 to 5,000,000.
5New individual limits were imposed on performance units granted under the amended 2004 Equity Incentive Plan, capping grants to 200,000 shares per employee per year, with exceptions for new hires and promotions.
6The Gilead Sciences, Inc. Code Section 162(m) Bonus Plan, initially adopted in late 2005, received stockholder approval and became effective January 1, 2006, establishing performance-based bonus criteria.
7The number of authorized Series A Junior Participating Preferred Stock shares was increased from 400,000 to 800,000.

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (May 11, 2006)

Summary

Key Highlights

Frequently Asked Questions